Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:SRPT). Here's what you need to know.
Arrowhead Pharmaceuticals Inc.（纳斯达克：ARWR）的股票在周二上涨，此前该公司与Sarepta Therapeutics Inc.（纳斯达克：SRPT）宣布了一项全球许可和合作协议。以下是你需要知道的。
What To Know: The partnership grants Sarepta exclusive worldwide rights to Arrowhead's investigational RNA interference (RNAi) therapies for rare genetic diseases targeting muscle, the central nervous system (CNS) and the lungs.
要点：该合作伙伴关系授予Sarepta对Arrowhead用于治疗针对肌肉、中枢神经系统（CNS）和肺部的稀有遗传疾病的实验性RNA干扰（RNAi）疗法的全球独家权利。
The agreement focuses on Arrowhead's Targeted RNAi Molecule platform, which enables precise delivery of therapies designed to reduce the activity of disease-causing genes.
该协议侧重于Arrowhead的靶向RNAi分子平台，该平台能够精确地递送旨在减少致病基因活性的疗法。
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.
Arrowhead将获得50000万美元的预付款，以及Sarepta以35%的溢价进行的32500万美元股权投资。其他条款包括在五年内支付的25000万美元，将在5000万美元的分期付款中支付，以及在未来一年内最多30000万美元的短期里程碑付款和潜在的商业销售分级版税。
Arrowhead CEO Christopher Anzalone called the agreement transformative, noting that the influx of capital extends the company's financial runway through 2028. This timeline positions Arrowhead to pursue the commercial launch of its first product, plozasiran, pending regulatory approval.
Arrowhead首席执行官Christopher Anzalone称该协议具有变革性，指出资本的流入将公司的财务承受能力延长至2028年。这一时间表使Arrowhead能够在监管批准后追求其首个产品plozasiran的商业发布。
Sarepta sees the collaboration as a strategic expansion of its portfolio, complementing its expertise in gene therapy and Duchenne muscular dystrophy. Sarepta CEO Doug Ingram highlighted the potential for these RNAi programs to have a significant market impact. As part of the agreement, Ingram will join Arrowhead's Board of Directors.
Sarepta将此次合作视为其组合的战略扩展，补充其在基因治疗和杜氏肌营养不良症方面的专业知识。Sarepta首席执行官Doug Ingram强调，这些RNAi项目对市场产生重大影响的潜力。作为协议的一部分，Ingram将加入Arrowhead的董事会。
"The agreement affords multiple potential blockbuster opportunities, serves our strategic priorities for the remainder of the decade and beyond and diversifies our business model across one-time therapies and chronic treatments allowing for long-term growth and success," Ingram said.
“该协议提供了多个潜在的块头型机会，符合我们在本十年内及更长时期的战略优先事项，并多元化了我们的业务模式，涵盖一次性疗法和慢性治疗，从而允许长期增长和成功，”Ingram说。
The collaboration is expected to close in early 2025, pending regulatory approval. Both companies have emphasized the agreement's significance in advancing treatments for rare genetic diseases, with additional details anticipated in their upcoming investor presentations.
该合作预计将在2025年初完成，待监管批准。两家公司都强调了该协议在推动稀有遗传疾病治疗方面的重要性，期待在他们即将进行的投资者演示中提供更多细节。
ARWR Price Action: Arrowhead Pharmaceuticals shares were up 16.7% at $21.94 at the time of writing, according to Benzinga Pro.
ARWR价格走势：根据Benzinga Pro的数据，arrowhead pharmaceuticals的股票在撰写时上涨了16.7%，达到21.94美元。
- Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M
- 合并中的Berry Global同意以约5.4亿美元出售特种胶带部门
Image Via Shutterstock.
图片来自Shutterstock。
